Welcome to our dedicated page for Strata Skin Sciences news (Ticker: SSKN), a resource for investors and traders seeking the latest updates and insights on Strata Skin Sciences stock.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company focused on in-office dermatologic devices, and its news flow reflects that specialization. Company announcements frequently highlight developments related to its core technologies: the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClearX® Acne Therapy System. These updates often cover new clinical evidence, regulatory milestones, reimbursement decisions, and commercial expansion in dermatology markets.
Investors and clinicians following SSKN news can expect regular coverage of peer-reviewed studies involving XTRAC in conditions such as psoriasis, vitiligo, atopic dermatitis, and mycosis fungoides, including combination regimens with topical drugs and JAK inhibitors. STRATA frequently reports on published data that it believes support the safety, efficacy, and personalized use of excimer laser therapy across a range of inflammatory and autoimmune skin diseases.
News items also address reimbursement and policy developments. STRATA has issued releases on CMS Medicare Physician Fee Schedule decisions related to CPT® codes 96920–96922, including continued coverage, payment levels, and recognition of future code descriptor expansions for excimer laser procedures. These updates are relevant for understanding how reimbursement may influence utilization of XTRAC in U.S. dermatology clinics.
Corporate and capital markets updates are another recurring theme. STRATA uses news releases to communicate quarterly financial results, non-GAAP performance metrics, registered direct offerings, and at-the-market equity programs. The company also reports on its legal and competitive positioning, including litigation milestones against competing device manufacturers and the recapture of dermatology clinics into its XTRAC partnership network.
International growth initiatives, such as COFEPRIS clearance for TheraClearX in Mexico and partnerships with commercialization firms like MINO Labs, appear in STRATA’s news as the company expands its device-based acne and phototherapy offerings beyond the United States. For users of this SSKN news page, the feed provides an ongoing view into STRATA’s clinical, regulatory, commercial, and financial developments in the dermatology device space.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced the launch of a new XTRAC® website on March 2, 2023. The site aims to enhance patient education about XTRAC excimer laser therapy for conditions like psoriasis and eczema. Key features include a Practice Finder tool, patient testimonials, and a Savings Program. CEO Bob Moccia emphasized the goal of increasing product awareness and improving patient access to treatment. The XTRAC device allows for targeted UVB light therapy, catering to a diverse patient base.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced on February 27, 2023, that it has regained compliance with Nasdaq's minimum bid price requirements under Rule 5550(a)(2). CEO Robert Moccia expressed optimism about the company's future growth prospects following this compliance notification. STRATA focuses on innovative products for dermatologic treatments, including the XTRAC and Pharos excimer lasers and the TheraClear X Acne Therapy System, employing a unique Partnership Program to facilitate treatment access. The company highlights its ongoing commitment to expand its product offerings and market presence.
HORSHAM, Pa., Feb. 16, 2023 - STRATA Skin Sciences (NASDAQ: SSKN) announced Dr. Joel L. Cohen will demonstrate the TheraClear®X device for acne treatment at the Winter Clinical Conference in Miami from February 17-20, 2023. The TheraClearX, FDA-cleared for mild to moderate acne, combines vacuum technology and intense broadband light to deliver results after just two treatments, with a recommended 4-6 sessions for optimal outcomes. STRATA's partnership program provides practices with a fee per treatment cost structure, including training and marketing support. Forward-looking statements about the product and market strategies highlight potential uncertainties affecting performance.
STRATA Skin Sciences (NASDAQ: SSKN) announced preliminary revenue for 2022 between $35-$36 million, a 17-19% increase from $30 million in 2021, exceeding previous guidance of $33-$35 million. The company attributed this growth to enhanced XTRAC® usage, refurbishing underutilized devices, and expanding international sales. CEO Bob Moccia expressed optimism about maintaining this growth momentum into 2023. These figures are unaudited and could be revised before the full financial results, expected in March 2023.
STRATA Skin Sciences (NASDAQ: SSKN) announced that a poster detailing the efficacy of its TheraClearX acne system was accepted for presentation at the ODAC Dermatology Conference from January 12-15, 2023. The study involved 10 patients with mild to moderate acne who underwent tailored photopneumatic therapy (PPT). All participants experienced visible reductions in acne lesions, with improvements noted in skin texture and pore size. Most responded positively after 2-3 sessions, showcasing the system's efficacy and safety. The findings reinforce STRATA's commitment to advancing treatment options for acne.
STRATA Skin Sciences (NASDAQ: SSKN) has entered an exclusive agreement with MINO Labs to distribute its dermatological products in Mexico for three years. This partnership aims to tap into a nearly $300 million market for treating acne, psoriasis, and vitiligo, addressing a significant need as 80% of the Mexican population suffers from acne. MINO Labs brings over 20 years of experience in the pharmaceutical sector, ensuring effective distribution through established sales channels. This collaboration is expected to expand treatment options for patients in Mexico.
HORSHAM, Pa., Dec. 02, 2022 – STRATA Skin Sciences, a medical technology company focused on dermatologic treatments, announced its presentation at the Cantor Medical & Aesthetic Dermatology Conference on December 8, 2022, at 1:45 PM EST. The session, titled Aesthetically Pleasing & Medically Necessary, will explore leading devices in the field. STRATA Skin Sciences specializes in innovative products for conditions like psoriasis and acne, offering solutions like XTRAC® and TheraClear® systems via a unique partnership program.
STRATA Skin Sciences reported strong Q3 2022 financial results, achieving revenues of $9.4 million, a 22% increase from Q3 2021. International sales soared to $3.3 million, marking an 82% rise year-over-year. The company launched the TheraClear®X acne therapy system, positioning itself in the $5.5 billion acne treatment market. Despite this growth, gross profit fell to 61.6% of revenues, down from 69.7% in the same quarter last year. STRATA reiterated its 2022 revenue guidance of $33 million to $35 million.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology firm focused on dermatologic treatments, will release its Q3 2022 financial results on November 9, 2022. A conference call will follow at 4:30 PM EST to discuss the results and provide updates. The company offers innovative products such as the XTRAC® and Pharos® excimer lasers and the TheraClear® X Acne Therapy System, utilizing a unique partnership program that streamlines treatment accessibility for dermatologists.
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced its participation in two upcoming investor events: the Microcap Rodeo: Windy City Roundup 2022 on October 12, 2022, and the LD Micro Main Event XV on October 26, 2022. At these events, the company will showcase its innovative dermatology products, including the XTRAC® and TheraClear® systems, which target conditions like psoriasis, acne, and vitiligo, impacting over 31 million patients in the U.S. STRATA employs a unique Direct to Consumer advertising model to boost awareness and patient volume for its partner dermatology clinics.